Somatostatin in maturity-onset diabetes

Area of Science:

• Endocrinology
• Metabolic Disorders
• Diabetes Research

Background:

• Maturity-onset diabetes is characterized by insulin resistance and impaired glucose regulation.
• Hormonal imbalances, including insulin, glucagon, and growth hormone, play a critical role in diabetes pathophysiology.
• Somatostatin's effects on these hormones and glucose metabolism in diabetic individuals require further elucidation.

Purpose of the Study:

• To investigate the effects of somatostatin infusion on plasma levels of free fatty acids (FFA), glucagon, insulin, glucose, and growth hormone.
• To compare the hormonal and metabolic responses to somatostatin in nonobese and obese maturity-onset diabetic men.
• To evaluate the potential of somatostatin as a therapeutic agent for managing maturity-onset diabetes.

Main Methods:

• Six nonobese and six obese men with maturity-onset diabetes were studied.
• Plasma hormone and glucose levels were measured hourly over 24 hours during saline infusion and 24 hours of somatostatin infusion.
• A 3-hour period without infusion served as a baseline control.

Main Results:

• Somatostatin infusion led to a rise in plasma FFA, a suppression of plasma glucagon and insulin, and an increase in plasma glucose in both patient groups.
• Plasma growth hormone was suppressed in nonobese diabetics but not in obese diabetics, who already had low, stable levels.
• The observed hormonal changes persisted throughout the infusion period, affecting both postprandial and nocturnal glucose levels.

Conclusions:

• Somatostatin's ability to suppress insulin secretion and elevate blood glucose levels makes it unsuitable for controlling maturity-onset diabetes.
• The differential effect on growth hormone in obese versus nonobese diabetics suggests varying regulatory mechanisms.
• Further research into agents that can modulate hormone profiles without detrimental effects on glucose control is warranted for diabetes management.